MannKind (MNKD) Competitors $3.58 -0.16 (-4.28%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$3.60 +0.02 (+0.59%) As of 09:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNKD vs. LGND, BCRX, FOLD, CLDX, INVA, DVAX, OPK, NVAX, GERN, and RGLSShould you be buying MannKind stock or one of its competitors? The main competitors of MannKind include Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), OPKO Health (OPK), Novavax (NVAX), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry. MannKind vs. Its Competitors Ligand Pharmaceuticals BioCryst Pharmaceuticals Amicus Therapeutics Celldex Therapeutics Innoviva Dynavax Technologies OPKO Health Novavax Geron Regulus Therapeutics Ligand Pharmaceuticals (NASDAQ:LGND) and MannKind (NASDAQ:MNKD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment. Do analysts rate LGND or MNKD? Ligand Pharmaceuticals presently has a consensus target price of $146.14, indicating a potential upside of 29.84%. MannKind has a consensus target price of $10.33, indicating a potential upside of 188.64%. Given MannKind's stronger consensus rating and higher possible upside, analysts clearly believe MannKind is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00MannKind 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has more volatility and risk, LGND or MNKD? Ligand Pharmaceuticals has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, MannKind has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Is LGND or MNKD more profitable? MannKind has a net margin of 10.12% compared to Ligand Pharmaceuticals' net margin of -73.07%. Ligand Pharmaceuticals' return on equity of -7.83% beat MannKind's return on equity.Company Net Margins Return on Equity Return on Assets Ligand Pharmaceuticals-73.07% -7.83% -6.92% MannKind 10.12%-32.41%10.85% Do institutionals & insiders believe in LGND or MNKD? 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 7.0% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 3.0% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media favor LGND or MNKD? In the previous week, Ligand Pharmaceuticals and Ligand Pharmaceuticals both had 6 articles in the media. Ligand Pharmaceuticals' average media sentiment score of 0.90 beat MannKind's score of 0.62 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, LGND or MNKD? MannKind has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLigand Pharmaceuticals$167.13M12.99-$4.03M-$7.12-15.81MannKind$285.50M3.81$27.59M$0.1035.80 SummaryMannKind beats Ligand Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNKD vs. The Competition Export to ExcelMetricMannKindMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.14B$2.85B$5.48B$8.94BDividend YieldN/A2.69%5.38%4.12%P/E Ratio35.8021.1726.2219.74Price / Sales3.81262.85394.92109.12Price / Cash26.9541.8936.4957.06Price / Book-12.347.237.915.37Net Income$27.59M-$55.05M$3.15B$248.34M7 Day Performance-7.01%-0.60%0.75%1.67%1 Month Performance-16.55%3.77%3.46%4.56%1 Year Performance-28.83%2.20%34.60%18.42% MannKind Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNKDMannKind3.0655 of 5 stars$3.58-4.3%$10.33+188.6%-29.7%$1.14B$285.50M35.80400High Trading VolumeLGNDLigand Pharmaceuticals4.7324 of 5 stars$113.68-0.4%$146.14+28.6%+32.7%$2.19B$167.13M-15.9780BCRXBioCryst Pharmaceuticals4.4671 of 5 stars$8.96-4.3%$16.89+88.5%+34.9%$1.87B$450.71M-34.46530Trending NewsAnalyst ForecastAnalyst RevisionFOLDAmicus Therapeutics4.0388 of 5 stars$5.73-3.4%$16.22+183.1%-40.4%$1.76B$528.29M-63.66480CLDXCelldex Therapeutics2.7723 of 5 stars$20.35+0.3%$50.11+146.2%-45.6%$1.35B$7.02M-7.54150Positive NewsINVAInnoviva4.1263 of 5 stars$20.09+0.7%$55.00+173.8%+19.9%$1.26B$358.71M-19.89100DVAXDynavax Technologies4.4224 of 5 stars$9.92+0.1%$24.00+141.9%-9.9%$1.19B$277.25M-19.08350Positive NewsOPKOPKO Health4.4444 of 5 stars$1.32flat$2.75+108.3%+8.1%$1.05B$713.10M-18.852,997Positive NewsNVAXNovavax4.5121 of 5 stars$6.30-1.1%$17.00+169.8%-48.1%$1.02B$682.16M2.381,990GERNGeron3.2776 of 5 stars$1.41-5.4%$5.06+259.0%-68.2%$898.06M$76.99M-6.7170RGLSRegulus Therapeutics2.0556 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830Gap Up Related Companies and Tools Related Companies Ligand Pharmaceuticals Alternatives BioCryst Pharmaceuticals Alternatives Amicus Therapeutics Alternatives Celldex Therapeutics Alternatives Innoviva Alternatives Dynavax Technologies Alternatives OPKO Health Alternatives Novavax Alternatives Geron Alternatives Regulus Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNKD) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
